The Rockefeller University

Icahn School of Medicine at Mount Sinai

Intra-Cellular Therapies, Inc.

Other

Sloan-Kettering Institute for Cancer Research

Cincinnati Children's Hospital Medical Center

Centre National De La Recherche Scientifique

Université Paris Descartes

Manros Therapeutics

Paul Greengard

Anne Schaefer

Samuel E Gandy

Joseph D Buxbaum

Chan Lek Tan

Joseph Dougherty

Allen A Fienberg

Huaxi Xu

Per Svenningsson

Hung-Teh Kao

Barbara Porton

Gretchen L Snyder

Gregg L Caporaso

Myriam Heiman

Joseph P Doyle

Wenjie Luo

Peng Li

Lawrence P Wennogle

Gabriela Chiosis

Laurent Meijer

Gretchen Snyder

Nathaniel Heintz

Huazhong He

Nassima Oumata

Kenneth S Kosik

Hervé Galons

William Netzer

Danuta Zatorska

David Repaske

Nathanial Heintz

Shasta Sabo

Akinori Nishi

Fei Dou

Gen He

Hui-Quan Han

Adriana Ferreira

Marc Flajolet

James A Bibb

Angus C Nairn

Feng Liu

Natalia Starkova

Sergey V Rakhilin

Gilberto Fisone

Joseph D Dougherty

Joseph Pn Doyle

Karima Bettayeb

The invention is directed to compositions and methods for treating or reducing the likelihood of the development of epilepsy in an individual. The method comprises administering to the central nervous system of an individual in need of such treatment a therapeutically effective amount of an agent capable of increasing the expression and/or activity of miR-128.

Compositions and methods for modulating neuronal excitability and motor behavior

Methods and compositions are provided for translational profiling and molecular phenotyping of specific tissues, cells and cell subtypes of interest. The methods provided herein facilitate the analysis of gene expression in the selected subset present within a heterogeneous sample.

Methods and compositions for translational profiling and molecular phenotyping

Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain.

Treatment of neurodegenerative diseases through inhibition of HSP90

The invention provides a previously uncharacterized protein (gamma secretase activating protein or gSAP) that activates &#x3b3;-secretase to produce &#x3b2;-amyloid protein (A&#x3b2;). Deposition of A&#x3b2; has been associated with Alzheimer's disease and other pathologies. The invention thus additionally provides, e.g., screening methods and novel research tools, inhibitors of this novel protein, and methods of diagnosis, treatment and control of Alzheimer's disease and other neurodegenerative conditions associated with deposition of A&#x3b2;.

Regulatory proteins and inhibitors

The invention provides methods for treating A&#x3b2; peptide related disorders such as Alzheimer's disease comprising administering a therapeutically effective amount of a CK1 modulator to a patient in need thereof.

Methods for the treatment of A-&#x3b2; related disorders and compositions therefor

The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.

Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain

The present invention provides methods and compositions for modulating levels of amyloid-&#x3b2; peptide (A&#x3b2;) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate A&#x3b2; levels. The invention also provides modulation of A&#x3b2; levels via selective modulation (e.g., inhibition) of ATP-dependent &#x3b3;-secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an A&#x3b2;-related disorder, by administering a modulator of &#x3b3;-secretase, including, but not limited to, a selective inhibitor of ATP-dependent &#x3b3;-secretase activity or an agent that decreases the formation of active (or optimally active) &#x3b3;-secretase. The invention also provides the use of inhibitors of ATP-dependent &#x3b3;-secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.

Compositions and methods for prevention and treatment of amyloid-&#x3b2; peptide-related disorders

The present invention relates to the use of p11 as a drug target as well as a tool for the diagnosis, treatment and development of p11/5-HT receptor related disorders. The invention further relates to p11 knock-out animals as well as p11 transgenic animals and their use as models for the development of novel psychotherapeutic agents, and to methods of diagnosis, prophylaxis and treatment of p11/5-HT receptor related disorders.

Diagnosis of depression

The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.

Method for classification of anti-psychotic drugs

Growing community of inventors

New York, NY, United States of America

Paul Greengard